Further, the consistent finding of a poorer prognosis with increasing tumour size within all levels of IHC subtype and grade, also among low-grade ER+HER2− tumours, suggests that late diagnosis will compromise survival regardless of IHC subtype and grade. This evidence concerns the gene ERBB2 and neoplasm.